Intelligence · Clinical Development
Pipeline search results
Programs matching “Celgene Europe” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 45 pipeline programs matching "Celgene Europe" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
ACE-536-LTFU-001
Celgene Europe Limited
myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibrosis (MF)
1 trial -
ACE-536-MF-002
Celgene Europe Limited
Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)
1 trial -
BB2121-MM-003
Celgene Europe Limited
Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.
1 trial -
CA0561060
Celgene Europe Limited
Myelodysplastic syndrome
1 trial -
CA057-001
Celgene Europe Limited
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
CA058-1019
Celgene Europe Limited
Relapsed and/or Refractory Multiple Myeloma
1 trial -
CA071-1000
Celgene Europe Limited
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1 trial -
CA073-1003
Celgene Europe Limited
Relapsed/Refractory Follicular Lymphoma
1 trial -
CA073-1020
Celgene Europe Limited
High-risk Large B-cell Lymphoma
1 trial -
CA088-1007
Celgene Europe Limited
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
1 trial -
CC-220-MM-002
Celgene Europe Limited
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
Cendakimab
Celgene Europe Limited
Eosinophilic esophagitis
1 trial -
FEDR-MF-002
Celgene Europe Limited
Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-essential thrombocythemia myelofibrosis
1 trial -
IM047-023
Celgene Europe Limited
Moderately to Severely Active Crohn's Disease
1 trial -
Lenalidomide
Celgene Europe Limited
B-cell Chronic Lymphocytic Leukemia
1 trial -
Ozanimod, Ozanimod
Celgene Europe Limited
Ulcerative colitis
1 trial -
Ozanimod, Ozanimod
Celgene Europe Limited
Moderately to Severely Active Crohn's Disease
1 trial -
RPC01-3203
Celgene Europe Limited
Moderately to Severely Active Crohn's Disease
1 trial -
Thalidomide
Celgene Europe Limited
Multiple Myeloma
1 trial -
ACE-536
Celgene Europe Limited
Beta-Thalassemia
1 trial -
AG-221-AML-005
Celgene Europe Limited
Acute Myeloid Leukemia (AML)
1 trial -
CA057-003
Celgene Europe Limited
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
CA057-1040
Celgene Europe Limited
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
CA058-002
Celgene Europe Limited
Relapsed and/or Refractory Multiple Myeloma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.